Home > Insider Trading > Filing (0000899243-17-018090)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1420565	Aileron Therapeutics Inc	ALRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1710065	Aju Ib Investment Co., Ltd.	800 Boylston St., Suite 3310 Boston MA 02199		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-05	443,973	$0.00	443,973	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-07-05	48,656	$0.00	492,629	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-07-05	24,929	$15.00	517,558	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series E-3 Preferred Stock	Disposition	2017-07-05	4,411,765	$0.00	443,973	$0.00
Common Stock	Series F Preferred Stock	Disposition	2017-07-05	483,501	$0.00	48,656	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person").
The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person.